Back to Browse Journals » Clinical Interventions in Aging » Volume 4

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Authors Rajni Sethi, Nicholas Sanfilippo

Published Date June 2009 Volume 2009:4 Pages 259—267

DOI http://dx.doi.org/10.2147/CIA.S4885

Published 5 June 2009

Rajni Sethi, Nicholas Sanfilippo

Department of Radiation Oncology, New York University Langone Medical Center, New York, NY, USA

Abstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.

Keywords: prostate cancer, leuprorelin, hormonal deprivation therapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Discrimination between biological interfaces and crystal-packing contacts

Yuko Tsuchiya, Haruki Nakamura, Kengo Kinoshita

Advances and Applications in Bioinformatics and Chemistry 2008, 1:99-113

Published Date: 2 November 2008

Management of osteoporosis in the aging male: Focus on zoledronic acid

Paul K Piper Jr, Ugis Gruntmanis

Clinical Interventions in Aging 2009, 4:289-303

Published Date: 17 June 2009

Restless legs syndrome: differential diagnosis and management with pramipexole

Francesca Brindani, Francesca Vitetta, Franco Gemignani

Clinical Interventions in Aging 2009, 4:305-313

Published Date: 18 June 2009

Tenofovir-associated bone density loss

Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Therapeutics and Clinical Risk Management 2010, 6:41-47

Published Date: 24 December 2009

Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene

Luigi Gennari, Daniela Merlotti, Ranuccio Nuti

Clinical Interventions in Aging 2010, 5:19-29

Published Date: 28 January 2010

Facial rejuvenation for middle-aged women: a combined approach with minimally invasive procedures

Alberto Goldman, Uwe Wollina

Clinical Interventions in Aging 2010, 5:293-299

Published Date: 14 September 2010

Elderly quality of life impacted by traditional chinese medicine techniques

Helena A Figueira, Olivia A Figueira, Alan A Figueira, et al

Clinical Interventions in Aging 2010, 5:301-305

Published Date: 1 October 2010

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor

Mannu P, Rinaldi S, Fontani V, Castagna A

Neuropsychiatric Disease and Treatment 2011, 7:373-379

Published Date: 15 June 2011

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012